Cargando…
Nrf2: a dark horse in doxorubicin-induced cardiotoxicity
Being a broad-spectrum anticancer drug, doxorubicin is indispensable for clinical treatment. Unexpectedly, its cardiotoxic side effects have proven to be a formidable obstacle. Numerous studies are currently devoted to elucidating the pathological mechanisms underlying doxorubicin-induced cardiotoxi...
Autores principales: | Zhao, Xiaopeng, Tian, Zheng, Sun, Mingli, Dong, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372151/ https://www.ncbi.nlm.nih.gov/pubmed/37495572 http://dx.doi.org/10.1038/s41420-023-01565-0 |
Ejemplares similares
-
Nrf2 Deficiency Exaggerates Doxorubicin-Induced Cardiotoxicity and Cardiac Dysfunction
por: Li, Siying, et al.
Publicado: (2014) -
Role of acetylation in doxorubicin-induced cardiotoxicity
por: Li, Daisong, et al.
Publicado: (2021) -
Dimethyl Fumarate Ameliorates Doxorubicin-Induced Cardiotoxicity By Activating the Nrf2 Pathway
por: Hu, Xiaoliang, et al.
Publicado: (2022) -
Protective effect of cafestol against doxorubicin-induced cardiotoxicity in rats by activating the Nrf2 pathway
por: Al-Kenany, Sara A., et al.
Publicado: (2023) -
The true colors of autophagy in doxorubicin-induced cardiotoxicity
por: Xiao, Bin, et al.
Publicado: (2019)